Summary by Moomoo AI
BioVie Inc., a clinical-stage company focusing on the development of drug therapies for neurological and neurodegenerative disorders as well as advanced liver disease, has announced the offering of Class A common stock and pre-funded warrants to purchase Class A common stock. The offering is being facilitated by ThinkEquity LLC, acting as the exclusive placement agent. The event is part of a broader strategy to raise capital for working capital and general corporate purposes. The pre-funded warrants will be immediately exercisable and may be exercised at any time until fully exercised. The offering is expected to be completed in 2024, subject to customary closing conditions. BioVie's common stock is traded on The Nasdaq Capital Market under the symbol 'BIVI.' The company has not disclosed the number of shares or warrants being offered or the offering price at this time.